<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909883</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0051</org_study_id>
    <nct_id>NCT00909883</nct_id>
  </id_info>
  <brief_title>Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)</brief_title>
  <acronym>RBHP 2008</acronym>
  <official_title>Foot Dystonia Treatment by Botulinum Toxin Injections in Parkinson Disease : Efficiency of Injections Made in Extrinsic Muscle (Flexor Digitorum Longus Muscle) Compared to Intrinsic Muscle (Flexor Digitorum Brevis or Quadratus Plantae Muscles)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Foot dystonia is frequently observed in patients suffering from Parkinson'disease. It is&#xD;
      characterized by an abnormal involuntary movement which is very uncomfortable (difficult to&#xD;
      walk) and painful for the patient.&#xD;
&#xD;
      Botulinum toxin injections seem to be efficient to treat this dystonia. However studies on&#xD;
      this topic are few and very imprecise (many muscle injected, especially the Flexor digitorum&#xD;
      longus, different doses used, heterogeneous population with many types of dystonia included,&#xD;
      open studies).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study progress :&#xD;
&#xD;
      After an inclusion visit, patients are randomized in one of the 3 following groups :&#xD;
&#xD;
        -  First group (PL : placebo) :&#xD;
&#xD;
             -  J0 : Patient will receive 1 injection of placebo in the Flexor digitorum longus and&#xD;
                1 injection of placebo in the Flexor digitorum brevis or in the quadratus plantae&#xD;
&#xD;
             -  J+1month : First evaluation&#xD;
&#xD;
             -  J+3 months : Patient will receive again 1 injection of placebo in the Flexor&#xD;
                digitorum longus and 1 injection of placebo in the Flexor digitorum brevis or in&#xD;
                the quadratus plantae&#xD;
&#xD;
             -  J+4 months : Last evaluation&#xD;
&#xD;
        -  Second group (ME : Extrinsic muscle)&#xD;
&#xD;
             -  J0 : Patient will receive 1 injection of Botulinum toxin (100U) in the Flexor&#xD;
                digitorum longus and 1 injection of placebo in the Flexor digitorum brevis or in&#xD;
                the quadratus plantae&#xD;
&#xD;
             -  J+1 month : First evaluation&#xD;
&#xD;
             -  J+3 months : Patient will receive again 1 injection of Botulinum toxin (100U) in&#xD;
                the Flexor digitorum longus and 1 injection of placebo in the Flexor digitorum&#xD;
                brevis or in the quadratus plantae&#xD;
&#xD;
             -  J+4 months : Last evaluation&#xD;
&#xD;
        -  Third group (MI : Intrinsic muscle)&#xD;
&#xD;
             -  J0 : Patient will receive 1 injection of placebo in the Flexor digitorum longus and&#xD;
                1 injection of Botulinum toxin (100U) in the Flexor digitorum brevis or in the&#xD;
                quadratus plantae&#xD;
&#xD;
             -  J+1 month : First evaluations&#xD;
&#xD;
             -  J+3 months : Patient will receive again 1 injection of placebo in the Flexor&#xD;
                digitorum longus and 1 injection of Botulinum toxin (100U) in the Flexor digitorum&#xD;
                brevis or in the quadratus plantae&#xD;
&#xD;
             -  J+4 months : Last evaluations&#xD;
&#xD;
      During injections (J0 and J+3M), we will measure the pain induced by injections (EVA) For&#xD;
      each evaluation (J+1M and J+4M), following evaluations will be made: clinical improvement&#xD;
      (CGI), dystonia evaluation (duration and severity, Burke scale), pain (EVA) and quality of&#xD;
      life (PDQ39).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In a controlled double blind and randomized study, we want to show that intramuscular injections of botulinum toxin are beneficial to reduced dystonia and associated pain in patient with foot dystonia (compared to placebo injections).</measure>
    <time_frame>one month after the injection of botulinum toxin/placebo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficiency comparison of injections made in leg muscle (Flexor digitorum longus) between injections made directly in foot muscle (Flexor digitorum brevis or quadratus plantae) - Effects of injections on pain and quality of life.</measure>
    <time_frame>one month after injections of placebo or Botulinum toxin</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Foot Dystonia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin: Xeomin</intervention_name>
    <description>45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injection</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age : 30-75 years&#xD;
&#xD;
          -  Patient with an idiopathic Parkinson's disease according to the criteria of the&#xD;
             &quot;Parkinson's Disease Society Brain Bank&quot;&#xD;
&#xD;
          -  Patient with unilateral tiptoe dystonia. Dystonia must be present more than 1h /day&#xD;
             and induce difficulties to walk (severity index ≥ 3 (1 : light, 2 : moderate, 3 :&#xD;
             severe, 4 : very severe)).&#xD;
&#xD;
          -  Patients never treated with botulinum toxin or already treated for more than 6 months.&#xD;
&#xD;
          -  Affiliation to social security&#xD;
&#xD;
          -  Agreement of patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients suffering of an atypical Parkinson syndrome&#xD;
&#xD;
          -  Patient with a bilateral tiptoe dystonia&#xD;
&#xD;
          -  Patients with contraindication to the botulinum toxin use&#xD;
&#xD;
          -  Women without efficient contraception&#xD;
&#xD;
          -  Person who participate to an other study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Durif</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick Lacarin</last_name>
    <phone>04.73.75.11.95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Gabriel-Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Levêque</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2009</study_first_posted>
  <last_update_submitted>March 24, 2011</last_update_submitted>
  <last_update_submitted_qc>March 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Pr Franck DURIF</name_title>
    <organization>CHU Clermont-Ferrand</organization>
  </responsible_party>
  <keyword>Idiopathic Parkinson's disease</keyword>
  <keyword>Foot (Tiptoe) dystonia</keyword>
  <keyword>Botulinum Toxin</keyword>
  <keyword>Muscles : Flexor digitorum longus/ Flexor digitorum brevis/ quadratus plantae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

